AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its own clinical development and regulatory expertise to advance selected programs.
- Under the deal, insitro will receive $40 million upfront under the agreement.
- The company is eligible for up to approximately $1.46 billion in potential development and commercial milestone payments, plus potential single-digit royalties on global sales.
- AstraZeneca will have exclusive worldwide rights to advance selected programs identified through the collaboration.
AstraZeneca (AZN) announced on Thursday a strategic drug discovery collaboration and licensing agreement with insitro, an AI-driven drug discovery company, to identify potential treatments for liver and heart diseases.
Under the agreement, insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in potential development and commercial milestone payments, plus potential single-digit royalties on global sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.